This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Brief Report

Lithium Beyond Bipolar Mood Disorders: A Hope or Hype?

Ahmed Naguy, MBBch, MSc,a,* and Bibi Alamiri, MD, ABPN, ScDa

Published: September 8, 2022


Prim Care Companion CNS Disord 2022;24(5):21br03109

To cite: Naguy A, Alamiri B. Lithium beyond bipolar mood disorders: a hope or hype? Prim Care Companion CNS Disord. 2022;24(5):21br03109.
To share: https://doi.org/10.4088/PCC.21br03109

© 2022 Physicians Postgraduate Press, Inc.

aAl-Manara CAP Centre, Kuwait Centre for Mental Health, Shuwaikh, Kuwait
*Corresponding author: Ahmed Naguy, MBBch, MSc, Al-Manara CAP Centre, Kuwait Centre for Mental Health, Jamal Abdul-Nassir St, Shuwaikh, Sulibikhat 21315, Kuwait (ahmednagy@hotmail.co.uk).

 

 

Lithium remains the only agent with double-blind evidence of efficacy in all 4 phases of bipolar mood disorder—an epitome of a “mood stabilizer” in the strictest sense. By virtue of its composite mode of action (Table 1), lithium might be the only disease-modifying psychotropic agent. It has been shown to prolong lives by preventing completed suicide in bipolar mood disorder by 6-fold (and possibly recurrent unipolar depression as well by 5-fold) and decreasing cardiovascular mortality.1 It is US Food and Drug Administration approved in patients as young as age 7 years and is available in different salt formulations (carbonate, citrate, and orotate).

Lithium antisuicidality might be related to its thymoleptic actions and true prophylaxis of mood episodes but also to anti-impulsive and antiaggressive actions, procognitive actions and improved decision-making performance, increased glutamine synthetase expression, and, conceivably, increased access to clinical care for mandatory serum monitoring.1 Lithium, especially in geriatric bipolar mood disorder, transcends efficacy data on neuroprotection and reduction in risk of dementia and strokes by virtue of its demonstrated anti-inflammatory, antioxidant, and endothelial actions.2

Recently, data from neuroscience have confirmed lithium’s procognitive actions.3 These actions include inter alia; increased gray matter volume; promotion of hippocampal neurogenesis; increased N-acetylaspartate, which is a putative marker of neuronal viability; increased brain-derived neurotropic factor and vascular endothelial growth factor; increased antiapoptotic Bcl-2; inhibition of proapoptotic protein P53 and β-catenin; inhibition of GSK-3β; inhibition of caspase-3 pathway; boosted cholinergic tone in the cortex; and better white matter integrity.

Moreover, lithium’s demonstrated neuroprotectant actions can be in part related to modulating γ-aminobutyric acid–mediated calcium influx, which is a relevant mechanism to neurodegenerative disorders. Research suggests a positive influence of lithium on the deposit of α-synuclein and β-amyloid proteins—hallmarks of Parkinson’s and Alzheimer’s diseases, respectively.3 Due to the diversity of lithium’s pharmacologic portfolio, it is obvious that lithium might be a promising therapeutic option in numerous disorders, although solid scientific evidence is lacking for most of these potential albeit off-label indications to date.

Clinical uses of lithium in psychiatry are protean apart from bipolar mood disorders. These clinical uses include anti-impulsivity, antisuicidality, antiaggressivity, dual diagnoses, schizoaffective disorder, augmentation in unipolar depression, cyclothymia, cycloid psychosis, Klein-Levine syndrome, borderline personality disorder, clozapine-induced neutropenia (it increases colony-stimulating factors, stimulates proliferation of pluripotent stem cells and granulopoiesis/megakaryocytopoiesis), augmentation in schizophrenia, and psychogenic polydipsia, just to name few.4

Even beyond psychiatric indications, lithium has been trialed successfully in many medical conditions including cluster/hypnic headaches, Felty syndrome, gout, Huntington’s disease, thyrotoxicosis, seborrheic dermatitis (topical), Herpes simplex, syndrome of inappropriate antidiuretic hormone secretion, Canavan disease, cyclic vomiting, and asthma.5,6 Nonetheless, use in some of these indications remains largely of historical interest.

Of note, typical dosing, serum level of lithium, and duration to obtain targeted response in these diverse indications, beyond bipolar mood disorders (wherein serum lithium concentration of 0.8–1.2 mmol/L is generally optimal), are largely unknown. Some authors7 suggest a low lithium dose of 150–300 mg/d (corresponding to 0.1–0.4 mmol/L) for suicide prevention and neuroprotection in dementia.

That said, lithium is globally underutilized given its narrow therapeutic index, mandatory monitoring, concerns about long-term end-organ effects (eg, hypothyroidism, nephrogenic diabetes insipidus, hyperparathyroidism, weight gain, teratogenicity), and comedications that have potentially hazardous interactions (eg, nonsteroidal anti-inflammatories, angiotensin converting enzyme/angiotensin receptor blockers, diuretics, metronidazole).8–11 It is incumbent on prescribers to renounce aversive attitudes regarding lithium in the best interest of our patients.

Submitted: August 21, 2021; accepted November 4, 2021.
Published online: September 8, 2022.
Relevant financial relationships: None.
Funding/support: None.

Volume: 24

Quick Links: Bipolar Disorder

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...